{"id":"W4411281412","doi":"10.1080/14796694.2025.2511470","title":"LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research","funders":"Genentech; Astellas Pharma; Eisai; EMD Serono; Rakuten Medical; Daiichi Sankyo Europe; Sanofi; Exelixis; Amgen; Relay Therapeutics; Gilead Sciences; Pfizer; Break Through Cancer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Agios Pharmaceuticals","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001984662,0.001004375,0.001352057,0.0003400813,0.0003969171,0.0009962465,0.0008675911,0.001501905,0.003825267],"category_scores_gemma":[0.0007860354,0.0005176293,0.001636862,0.000281153,0.0008041591,0.0008472992,0.0003178965,0.002665319,0.0007084146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001280655,"about_ca_system_score_gemma":0.001477391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001561349,"about_ca_topic_score_gemma":0.005724066,"domain_scores_codex":[0.9994181,0.0003005352,0.00002918422,0.00007387189,0.00006230878,0.0001159664],"domain_scores_gemma":[0.9995744,0.00006266686,0.00009344499,0.00004424202,0.00004156819,0.0001837602],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8000542,0.03900387,0.002458086,0.001446558,0.002160017,0.0001755098,0.0002828329,0.002639632,0.04431905,0.0008936111,0.007063773,0.09950292],"study_design_scores_gemma":[0.6608912,0.3194561,0.005709018,0.0001088097,0.0006229059,0.0001810577,0.00008795119,0.001144429,0.005404313,0.0004139691,0.005945072,0.00003519288],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9779652,0.006149544,0.0008967232,0.0008027037,0.0003443213,0.00558032,0.001829226,0.0002689926,0.006163009],"genre_scores_gemma":[0.9724291,0.004212117,0.002962693,0.001805591,0.0001829195,0.005904149,0.003650015,0.00005440757,0.008798931],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003825267,"threshold_uncertainty_score":0.01279682,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04745932149046059,"score_gpt":0.4257728950944811,"score_spread":0.3783135736040205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}